期刊文献+

DH3初筛阳性在宫颈高危病变中的临床意义 被引量:1

Clinical Significance of DH3 Positive Screening in High-risk Cervical Lesions
下载PDF
导出
摘要 目的:探讨DH3(人乳头瘤病毒杂交捕获—化学发光法核酸检测试剂盒)初筛阳性在宫颈高危病变中的临床意义。方法:回顾性统计我院2017年6月—2018年8月门诊或体检行DH3筛查的患者,其中175例DH3阳性的患者作为研究对象,以病理活检为金标准,统计DH3阳性结果的病变分布情况。结合TCT的检查结果,探讨细胞学在DH3阳性结果的分流作用,同时运用统计学分析年龄、病毒负荷量与宫颈高危病变的关系。结果:DH3阳性率15.95%,病理学示175例DH3阳性患者中,炎症63例(36.00%),LSIL42例(24.00%),HSIL44例(25.14%),宫颈癌(鳞癌及腺癌)26例(14.86%),宫颈高危病变(≥HSIL)率40.00%,DH3阳性预测值64.00%;宫颈高危病变率在年龄组20~30岁、30~40岁、40~50岁、50~60岁、>60岁中分别为12.50%、25.58%、45.61%、53.13%、68.42%,宫颈高危病变随年龄增加而增高,组间差异有统计学意义(χ~2=22.863,P<0.05);宫颈高危病变率在HPV负荷量分组≤10、10~30、30~60、60~100、>100中分别为14.89%,28.57%、47.62%58.35%、55.41%,宫颈高危病变随高危病毒感染量增加而增高,组间差异有统计学意义(χ~2=22.026,P<0.05);157例DH3阳性患者同时行TCT及病理活检,TCT阳性病变(≥ASC-US)83例,阳性率52.87%,组织学阳性病变(≥LSIL)97例,阳性率61.78%,TCT与组织学一致率为74.52%(117/157)。结论:DH3是宫颈高危病变筛查的可行方法,随着年龄及感染病毒负荷量的增加,宫颈高危病变发生率增加,TCT对DH3阳性患者分流有重要指导意义,但同时也需关注患者年龄及病毒负荷量对宫颈高危病变的影响。 Objective:To investigate the clinical significance of DH3(human papillomavirus hybridization capture-chemiluminescence nucleic acid detection kit) positive screening in cervical high-risk lesions.Methods:A retrospective study was conducted on 175 DH3 positive patients in our hospital from June 2017 to August 2018. Pathological biopsy was used as the gold standard to calculate the distribution of DH3 positive results. Combined with the results of TCT, the shunting effect of cytology on DH3 positive results was discussed.Meanwhile, the relationship between age, viral load and cervical high-risk lesions was analyzed by statistics.Results:The positive rate of DH3 was 15.95%. Pathological examination showed that 63 cases(36.00%) were inflammation, 42 cases(24.00%) were LSIL, 44 cases(25.14%) were HSIL, 26 cases(14.86%) were cervical cancer(squamous cell carcinoma and adenocarcinoma), 40.00% were cervical high-risk lesions(>HSIL), 64.00% were DH3 positive predictive value;the high-risk lesion rate of cervix was 12.50%,25.58%,45.61%,53.13%,68.42%,respectively in age groups:20 to 30 years old, 30 to 40 years old, 40 to 50 years old,50 to 60 years old and over 60 years old, The high-risk cervical lesions increased with age(χ~2=22.863,P<0.05), and the high-risk cervical lesions rate was less 14.89%,28.57%,47.62%,58.35%,55.41%, respectively in HPV load groups:less than 10,10 to 30,30 to 60, 60 to 100,more than 100.Cervical high-risk lesions increased with the increase of high-risk virus infection(χ~2=22.026,P<0.05).157 DH3 positive patients underwent both TCT and pathological biopsy, the positive rate was 52.87% in TCT.97 cases were histologically positive(> LSIL), and the positive rate was 61.78%. The coincidence rate between TCT and histology was 74.52%(117/157).Conclusion:DH3 is a feasible method for screening high-risk cervical lesions.With the increase of age and viral load, the incidence of high-risk cervical lesions increases.TCT has improtant guiding significance for shunting of DH3 positive patients,but at the same time,attention should be paid to the influence of age and viral load on high-risk cervical lesions.
作者 何婷婷 阮萍 彭忠异 姚平 刘莹 HE Tingting;RUAN Ping;PENG Zhongyi(Department of Pathology,Ruikang Hospital,Guangxi University of Chinese Medicine,Nanning City,Guangxi 530011)
出处 《医学理论与实践》 2019年第6期803-805,813,共4页 The Journal of Medical Theory and Practice
关键词 人乳头瘤病毒 宫颈高危病变 筛查 分流 TCT HPV High-risk cervical lesions Screening Shunt TCT
  • 相关文献

参考文献7

二级参考文献73

  • 1周庆云 田芳 杜敏等.甘肃地区人乳头瘤病毒基因型与宫颈病变的相关性分析.中国优生优育,2011,:269-272.
  • 2温旺荣,李莉,钟玉婷,吴勇,曹燕.应用改良导流杂交法检测103例妇女HPV基因型[J].暨南大学学报(自然科学与医学版),2007,28(6):595-597. 被引量:11
  • 3Hooper JE, Hebert JF, Schilling A, et al. Hybrid Capture 2 is as effective as PCR testing for high-risk human papillomavirus in head and neck cancers[J]. Appl Immunohistochem Mol Morphol, 2015, 23 (4) : 266-272.
  • 4Ozaki S, Kato K, Abe Y, et al. Analytical performance of newly developed multiplex human papillomavirus genotyping assay using Luminex xMAPTM technology (Mebgen ? HPV Kit) [J]. J Virol Methods, 2014, 204: 73-80.
  • 5Militello V, Lavezzo E, Costanzi G, et al. Accurate human papillomavirus genotyping by 454 pyrosequencing [J] . Clin Microbiol Infect, 2013, 19(10) : E428434.
  • 6Alameda F, Garrote L, Mojal S, et al. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population [J]. Arch Pathol Lab Med, 2015, 139(2) : 241-244.
  • 7Munkhdelger J, Kim G, Wang HY, et al. Performance of HPV E6/E7 mRNA RT-qPCR for screening and diagnosis of cervical cancer with ThinPrep Pap test samples [J]. Exp Mol Pathol, 2014, 97 (2) : 279-284.
  • 8Ratnam S, Coutlee F, Fontaine D, et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer [J]. J Clin Microbiol, 2011, 49 (2) : 557-564.
  • 9Stoler MH, Wright TC Jr, Cuzick J, et al. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results [J]. Am J Obstet Gynecol, 2013, 208(2): 144. el-8.
  • 10李莉,林晓丹,温旺荣.茎环引物的SYBR GreenⅠ实时荧光定量PCR检测miR-155表达及其临床初步应用[J].检验医学,2010,25(4):296-300. 被引量:8

共引文献56

同被引文献15

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部